77
Views
18
CrossRef citations to date
0
Altmetric
Regular articles

Specific adsorption of the autoantibodies from rheumatoid arthritis patient plasma using histidine-containing affinity beads

, , , , &
Pages 875-892 | Published online: 02 Apr 2012
 

Abstract

Rheumatoid arthritis is characterized by chronic polyarthritis and destruction of multiple joints. In this study, poly(hydroxyethyl methacrylate-N-methacryloyl-(L-histidine)-methylester) (PHEMAH) beads were used in the removal of pathogenic antibodies from rheumatoid arthritis patient plasma in a packed bed column. PHEMAH beads, in the size range of 80–120 μm, were produced by suspension polymerization. The beads were contacted with blood in an in vitro system. Loss of blood cells and clotting times were followed. PHEMAH beads were characterized by scanning electron microscopy. We found that PHEMAH beads had a spherical shape and porous structure. Loss of cells in the blood contacting with PHEMAH beads was negligible. IgM-antibody adsorption capacity decreased significantly with the increase of the plasma flow-rate. With increasing IgM-antibody concentration, the amount of IgM-antibody adsorbed per unit mass increased and then reached saturation. Maximum IgM-antibody adsorption amount was 69.2 mg/g. IgM-antibody molecules could be repeatedly adsorbed and desorbed without noticeable loss in the IgM-antibody adsorption amount.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.